ArticleAnnals of hematology2026
Outcomes of gastrointestinal bleeding events after first-line chemotherapy in gastrointestinal-diffuse large B-cell lymphoma: a propensity-score matched analysis.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastrointestinal bleeding (GIB) is a life-threatening complication of first-line chemotherapy in gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL), yet its prognostic significance remains poorly defined. This propensity score-matched study (1:2) included 79 patients with GI-DLBCL, comparing 9 with post-chemotherapy GIB to controls without GIB. Matching was based on gender, clinical stage, Hans classification, and Eastern Cooperative Oncology Group (ECOG) performance status. Patients with GIB had worse overall survival (OS, P = 0.006) and progression-free survival(PFS, P = 0.011), with markedly lower complete (11.11% vs. 66.67%, P = 0.013) and objective (66.67% vs. 100.00%, P = 0.029) response rates. Higher baseline PET-CT parameters including gastrointestinal-metabolic tumor volume (GI-MTV, P = 0.002) and gastrointestinal-total lesion glycolysis (GI-TLG, P = 0.004) indicated GIB occurrence. In the survival analysis, high ECOG (P = 0.032), whole-body metabolic tumor volume (Wb-MTV, P = 0.012), and total lesion glycolysis (Wb-TLG, P = 0.038) might be associated with poor OS, while high ECOG (P = 0.008) and international prognostic index (IPI, P =0.027) were associated with poor PFS. GIB was successfully managed with conservative medical therapy in the majority of cases (77.78%), with the remainder (22.22%) requiring endoscopic hemostasis. Post-chemotherapy GIB in GI-DLBCL is associated with a poor prognosis, particularly in patients with elevated baseline PET/CT metabolic parameters indicative of high tumor burden.
Indexed as
Identifiers
42911419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.